Injectable Drug Delivery News

  1. Societal CDMO Signs Three-Year Manufacturing And Supply Agreement With InfectoPharm For Ritalin LA® In Europe 5/5/2022

    Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA® capsules (methylphenidate hydrochloride extended-release capsules) in Europe

  2. Stevanato Group And Owen Mumford Sign Exclusive Collaboration Agreement For The Innovative Aidaptus® Auto-Injector 5/4/2022

    The Aidaptus® disposable auto-injector platform, designed by Owen Mumford, will be jointly offered to global biopharma companies to support their drug development programs with engineering and manufacturing support provided by Stevanato Group.

  3. Grand River Aseptic Manufacturing Invests $160M With Award From U.S. Government To Support Continued And Future Growth 4/28/2022

    Grand River Aseptic Manufacturing ("GRAM"), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense

  4. CDMO Grand River Aseptic Manufacturing To Invest $160 Into Manufacturing Expansion In Michigan 4/28/2022

    Grand River Aseptic Manufacturing (“GRAM”), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense.

  5. Mithra CDMO Announces Collaboration With MedinCell For The Development Of Injectable Products For Malaria And Transplant Rejection 4/26/2022

    Mithra today announced a collaboration with MedinCell for the development of two long-acting injectable products in its CDMO based in Liège

  6. Dutch CDMO BioConnection Announces Substantial Investment By Gimv, Supported By Existing Shareholders 4/22/2022

    BioConnection, an independent CDMO (Contract Development Manufacturing Organization) based in Oss, The Netherlands, specialized in GMP-certified manufacturing of sterile drug products in vials and syringes, today announced the completion of a new capital raising led by the European investment company Gimv, and supported by existing shareholders Pharming Group N.V., Mibiton and BioConnection's own management

  7. INCOG BioPharma Completes Construction Of Cleanrooms, On Track To Manufacture Injectable Drug Products In Q3 2022 4/5/2022

    INCOG BioPharma Services, an Indiana-based contract development and manufacturing organization (CDMO) reached another major milestone in its facility by completing the construction of its cleanroom production area within the new 90,000 sq. ft. bio/pharmaceutical manufacturing site.

  8. Sanofi Announces €300 Million Collaboration With Blackstone Life Sciences To Advance An Innovative Treatment For Multiple Myeloma 3/15/2022

    Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma (MM).

  9. INCOG BioPharma Services Completes Analytical And Quality Control Testing Laboratory & Technology Transfer Suite 3/1/2022

    The newly designed analytical chemistry and microbiology laboratories will provide a wide range of essential biological and chemical testing capabilities to support sterile injectable drug product fulfillment programs, including sterility testing.

  10. Alcami Adds Additional Formulation Development Capabilities 3/1/2022

    Alcami, a U.S.-based pharmaceutical contract development and manufacturing organization (CDMO), announced today the addition of a 3,800 ft² Non-GMP Formulation Development Laboratory (FDL). The dedicated Non-GMP formulation development space, which is co-located within the same facility as Alcami's parenteral manufacturing operation that offers four isolator filling lines for liquid and lyophilized products, is ready to support customers with Preclinical and Clinical development programs.